Drugs / TDF
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05612581 Background | May 2023 → Oct 2024 | chronic hepatitis B virus infection | Vir Biotechnology, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TDF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05612581 ↗ |
| Route | Oral | “TDF given orally” NCT05612581 ↗ |